5244042025-07-012025-09-305244042025-09-305244042025-03-315244042025-04-012025-09-305244042025-07-012025-09-30in-capmkt:OtherExpenses1Member5244042025-04-012025-09-30in-capmkt:OtherExpenses1Member5244042025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15244042025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15244042025-07-012025-09-30RelatedPartyTransactionDomain15244042025-06-30RelatedPartyTransactionDomain15244042025-09-30RelatedPartyTransactionDomain15244042025-07-012025-09-30RelatedPartyTransactionDomain25244042025-06-30RelatedPartyTransactionDomain25244042025-09-30RelatedPartyTransactionDomain25244042025-07-012025-09-30RelatedPartyTransactionDomain35244042025-06-30RelatedPartyTransactionDomain35244042025-09-30RelatedPartyTransactionDomain35244042025-07-012025-09-30RelatedPartyTransactionDomain45244042025-06-30RelatedPartyTransactionDomain45244042025-09-30RelatedPartyTransactionDomain45244042025-07-012025-09-30RelatedPartyTransactionDomain55244042025-06-30RelatedPartyTransactionDomain55244042025-09-30RelatedPartyTransactionDomain55244042025-07-012025-09-30RelatedPartyTransactionDomain65244042025-06-30RelatedPartyTransactionDomain65244042025-09-30RelatedPartyTransactionDomain65244042025-07-012025-09-30RelatedPartyTransactionDomain75244042025-06-30RelatedPartyTransactionDomain75244042025-09-30RelatedPartyTransactionDomain75244042025-07-012025-09-30RelatedPartyTransactionDomain85244042025-06-30RelatedPartyTransactionDomain85244042025-09-30RelatedPartyTransactionDomain85244042025-07-012025-09-30RelatedPartyTransactionDomain95244042025-06-30RelatedPartyTransactionDomain95244042025-09-30RelatedPartyTransactionDomain95244042025-07-012025-09-30RelatedPartyTransactionDomain105244042025-06-30RelatedPartyTransactionDomain105244042025-09-30RelatedPartyTransactionDomain105244042025-07-012025-09-30RelatedPartyTransactionDomain115244042025-06-30RelatedPartyTransactionDomain115244042025-09-30RelatedPartyTransactionDomain115244042025-07-012025-09-30RelatedPartyTransactionDomain125244042025-06-30RelatedPartyTransactionDomain125244042025-09-30RelatedPartyTransactionDomain125244042025-07-012025-09-30RelatedPartyTransactionDomain135244042025-06-30RelatedPartyTransactionDomain135244042025-09-30RelatedPartyTransactionDomain135244042025-07-012025-09-30RelatedPartyTransactionDomain145244042025-06-30RelatedPartyTransactionDomain145244042025-09-30RelatedPartyTransactionDomain145244042025-07-012025-09-30RelatedPartyTransactionDomain155244042025-06-30RelatedPartyTransactionDomain155244042025-09-30RelatedPartyTransactionDomain155244042025-07-012025-09-30RelatedPartyTransactionDomain165244042025-06-30RelatedPartyTransactionDomain165244042025-09-30RelatedPartyTransactionDomain165244042025-07-012025-09-30RelatedPartyTransactionDomain175244042025-06-30RelatedPartyTransactionDomain175244042025-09-30RelatedPartyTransactionDomain175244042025-07-012025-09-30RelatedPartyTransactionDomain185244042025-06-30RelatedPartyTransactionDomain185244042025-09-30RelatedPartyTransactionDomain185244042025-07-012025-09-30RelatedPartyTransactionDomain195244042025-06-30RelatedPartyTransactionDomain195244042025-09-30RelatedPartyTransactionDomain195244042025-07-012025-09-30RelatedPartyTransactionDomain205244042025-06-30RelatedPartyTransactionDomain205244042025-09-30RelatedPartyTransactionDomain205244042025-07-012025-09-30RelatedPartyTransactionDomain215244042025-06-30RelatedPartyTransactionDomain215244042025-09-30RelatedPartyTransactionDomain215244042025-07-012025-09-30RelatedPartyTransactionDomain225244042025-06-30RelatedPartyTransactionDomain225244042025-09-30RelatedPartyTransactionDomain225244042025-07-012025-09-30RelatedPartyTransactionDomain235244042025-06-30RelatedPartyTransactionDomain235244042025-09-30RelatedPartyTransactionDomain235244042025-07-012025-09-30RelatedPartyTransactionDomain245244042025-06-30RelatedPartyTransactionDomain245244042025-09-30RelatedPartyTransactionDomain245244042025-07-012025-09-30RelatedPartyTransactionDomain255244042025-06-30RelatedPartyTransactionDomain255244042025-09-30RelatedPartyTransactionDomain255244042025-07-012025-09-30RelatedPartyTransactionDomain265244042025-06-30RelatedPartyTransactionDomain265244042025-09-30RelatedPartyTransactionDomain265244042025-07-012025-09-30RelatedPartyTransactionDomain275244042025-06-30RelatedPartyTransactionDomain275244042025-09-30RelatedPartyTransactionDomain275244042025-07-012025-09-30AuditorDomain15244042025-09-30Statement15244042025-07-012025-09-30Statement15244042025-09-30StatementDynamic1I1Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524404MARKSANSNOTLISTEDINE750C01026MARKSANS PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312025-11-132025-10-23INRMillionsQuarterlySecond quarterSingle segmentPharmaceutical Formulation2025-11-1317:40:002025-11-1318:40:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-02-11https://www.marksanspharma.com/pdf/Policy-on-materiality-of-related-party-transactions-and-on-dealing-with-related-party-transactions.pdftrue1falseThe Company has no outstanding loans and debt securities.2025-07-012025-09-30UnauditedStandalone320441000058189000037863000001466640000209860000-217300002845600003150000845600005443300002571370000121493000001214930000208050000882000021687000009980600000000998060000-74000099732000045316000012.22.2002.22.2NOTES TO STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF <BR> YEAR ENDED 30 SEPTEMBER 2025. <BR> <BR> 1. The standalone unaudited financial results for the quarter and half year ended 30 September 2025 <BR> were reviewed by the Audit Committee and approved by the Board of Directors at their respective <BR> meeting held on 13 November 2025. The Statutory Auditors of the Company have carried out <BR> limited review on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and <BR> Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended and expressed an <BR> unmodified conclusion. <BR> <BR> 2. The standalone unaudited financial results of the Company have been prepared in accordance <BR> with the recognition and measurement principles laid down in the Indian Accounting Standard 34 <BR> ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 read with <BR> relevant rules issued thereunder and other recognised accounting principles generally accepted in <BR> India and in terms of the Regulation. <BR> <BR> 3. The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind <BR> AS 108 on 'Operating Segments'. <BR> <BR> 4. Other income (net) includes the following net foreign exchange differences including forward contracts: <BR> <BR> Description Quarter ended Half year ended Year Ended <BR> 30-Sep-25 30-Jun-25 30-Sep-24 30-Sep-25 30-Sep-24 31-Mar-25 <BR> <BR> Net gain / (loss) 175.10 (37.73) (122.49) 137.37 (96.38) 194.80 <BR> <BR> 5. During half year ended 30 September 2025, the Board of Directors and Shareholders of the <BR> Company have approved the Marksans Employees Stock Option Scheme 2024 ("Scheme") for the <BR> employees of the Company and its subsidiary companies comprising of equity shares of the <BR> Company, not exceeding 2,300,000 equity share of face value of Re 1/- each. Under the said <BR> Scheme, the Company has granted 400,000 equity stock options of face value of Re 1/- each on 24 <BR> September 2025 to the eligible employees of the Company and its Subsidiary Companies. <BR> <BR> 2025-04-012025-09-30UnauditedStandalone640175000060199000070037400002919410000437840000-54640000563600000617000016644000011142500005153070000185067000001850670000353430000186200003720500000147862000000001478620000-1500000147712000045316000013.263.26003.263.26Other Expenses544330000Other Expenses111425000039541800000211400002658070000010610000266868000023464000068786400002012210000783000062097800008173100001819970000018850000887374000040387000011289820000181684600004531600001449753000014950690000149506900000843000008430000060970000139640000284910000021010000146447000014854800003132600001798740000971020000153200001477800002932860000321777000018168460000617000039890000-64698000001532100003690000-340000-600000-5512000000-9034000001664400000-11600003270000142200000-160070000386160000768500000763900000-4700000954500000-1354900000495770000000310910000018486000000000000262000032808000000000000000000000386160000809700000264750000406420000000000000014090000362530000000-376620000214660000-30000214630000602680000817310000Remeasurements of the net defined benefit liabilities/assets-1000000-1000000Remeasurements of the net defined benefit liabilities/assets-2010000-2010000-260000-510000Remeasurements of the net defined benefit liabilities/assets00Remeasurements of the net defined benefit liabilities/assets0000-740000-1500000Marksans Pharma Limited******Nova Pharmaceuticals Australasia Pty Ltd******SubsidiarySale of goods or services027328000000Marksans Pharma Limited******Nova Pharmaceuticals Australasia Pty Ltd******SubsidiaryAny other transactionReceivables037126000000Marksans Pharma Limited******Bell Sons & Co. (Druggists) Ltd******SubsidiarySale of goods or services023657000000Marksans Pharma Limited******Bell Sons & Co. (Druggists) Ltd******SubsidiaryAdvance04851000000Marksans Pharma Limited******Relonchem Limited******SubsidiarySale of goods or services082023000000Marksans Pharma Limited******Relonchem Limited******SubsidiaryAny other transactionReimbursement of Expenses07699000000Marksans Pharma Limited******Relonchem Limited******SubsidiaryAdvance082268000000Marksans Pharma Limited******Relonchem Limited******SubsidiaryPurchase of goods or services044000000Marksans Pharma Limited******Relonchem Limited******SubsidiaryAny other transactionPayables045000000Marksans Pharma Limited******Time Cap Laboratories Inc******SubsidiarySale of goods or services0433855000000Marksans Pharma Limited******Time Cap Laboratories Inc******SubsidiarySale of fixed assets051000000Marksans Pharma Limited******Time Cap Laboratories Inc******SubsidiaryAny other transactionReceivables0539872000000Marksans Pharma Limited******Time Cap Laboratories Inc******SubsidiaryPurchase of goods or services0721000000Marksans Pharma Limited******Time Cap Laboratories Inc******SubsidiaryAny other transactionPayables02186000000Marksans Pharma Limited******Marksans Pharma UK Limited******SubsidiaryDividend received038616000000Marksans Pharma Limited******Access Healthcare For Medical Products LLC******SubsidiaryAny other transactionReceivables0166000000Marksans Pharma Limited******Mark Saldanha******Managing DirectorRemuneration02611000000Marksans Pharma Limited******Mark Saldanha******Managing DirectorAny other transactionRent Paid0533000000Marksans Pharma Limited******Sandra Saldanha******Whole-time DirectorRemuneration0352000000Marksans Pharma Limited******Varddhman Vikramaditya Jain******Whole-time DirectorRemuneration01561000000Marksans Pharma Limited******Jitendra Sharma******Chief Financial OfficerRemuneration01211000000Marksans Pharma Limited******Harshavardhan Panigrahi******Company SecretaryRemuneration0151000000Marksans Pharma Limited******Abhinna Sundar Mohanty******Independent DirectorAny other transactionSitting Fees011000000Marksans Pharma Limited******Digant Mahesh Parikh******Independent DirectorAny other transactionSitting Fees030000000Marksans Pharma Limited******Shailaja Vardhan******Independent DirectorAny other transactionSitting Fees030000000Marksans Pharma Limited******Srinivas Mishra******Independent DirectorAny other transactionSitting Fees020000000Time Cap Laboratories Inc******Mark Saldanha******Managing DirectorRemuneration062300000012876410000UnauditedtrueMSKA & Associatestrue2027-07-31Preferential Issues2023-01-1837240000002025-09-30falsefalseNo deviation / variationSatisfactoryfalseHarshavardhan PanigrahiCompany Secretary and Compliance OfficerMumbai2025-11-12Expansion ProgrammeNo3724000000036701700000